科研
教育
解决方案
登录
CN
EN - English
CN - 中文
DE - Deutsch
ES - Español
KR - 한국어
IT - Italiano
FR - Français
PT - Português
TR - Turkish
JA - Japanese
Vicki G. Davis has not added Biography.
If you are Vicki G. Davis and would like to personalize this page please email our Author Liaison for assistance.
Change in metabolic syndrome parameters with antipsychotic treatment in the CATIE Schizophrenia Trial: prospective data from phase 1.
Schizophrenia research Apr, 2008 | Pubmed ID: 18258416
Impact of antipsychotic treatment on nonfasting triglycerides in the CATIE Schizophrenia Trial phase 1.
Schizophrenia research Aug, 2008 | Pubmed ID: 18534821
Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study.
Schizophrenia research Oct, 2008 | Pubmed ID: 18775645
Can a nonequivalent choice of dosing regimen bias the results of flexible dose double blind trials? The CATIE schizophrenia trial.
Schizophrenia research Aug, 2009 | Pubmed ID: 19545976
Inflammatory markers in schizophrenia: comparing antipsychotic effects in phase 1 of the clinical antipsychotic trials of intervention effectiveness study.
Biological psychiatry Dec, 2009 | Pubmed ID: 19640511
Treatment outcomes of patients with tardive dyskinesia and chronic schizophrenia.
The Journal of clinical psychiatry Mar, 2011 | Pubmed ID: 20816031
NeuroCog Trials, Inc.
Stacy A. Ruse1,
Vicki G. Davis1,
Alexandra S. Atkins1,
K. Ranga R. Krishnan2,3,
Kolleen H. Fox4,
Philip D. Harvey5,
Richard S.E. Keefe1,3
1, NeuroCog Trials, Inc.,
2, Duke-NUS Graduate Medical Center,
3, Duke University Medical Center,
4, Fox Evaluation and Consulting, PLLC,
5, University of Miami Miller School of Medicine
政策
使用条款
隐私
联系我们
向图书馆推荐
JoVE 新闻简报
JoVE Journal
技术专题合集
JoVE Encyclopedia of Experiments
档案
JoVE Core
JoVE Business
JoVE Science Education
JoVE Lab Manual
教师资源中心
发表
图书馆员
访问权限
关于 JoVE
版权所属 © 2024 MyJoVE 公司版权所有，本公司不涉及任何医疗业务和医疗服务。
